Satellite Industry Sponsored Symposia

ANR2018 Satellite Industry Sponsored Symposia

Please find information below on the Satellite Industry Sponsored Symposia that have been confirmed to-date for ANR2018. This information will be updated as the conference nears.

Registration to both symposia are free. Please note that lunch will be provided to the first 100 fully paid ANR Meeting registrants. To attend, please indicate when registering. 

Anti-GD2 Therapy for Neuroblastoma: Present and Future

Wednesday May 9, 2018, 11:30AM-1:00 PM

Paul Sondel, MD (University of Wisconsin, USA)

– Holger Lode, MD, PhD (University of Greifswald, Germany)
Julie Park, MD (University of Washington, USA)
Alice Yu, MD PhD (University of California, USA)
Paul Sondel, MD (University of Wisconsin, USA)


Strategies For Improving Neuroblastoma Outcome Using Anti-GD2 Immunotherapy

Julie Park will summarize recent data from COG studies that have combined anti-GD2 mAb with chemotherapy and present the COG approach for moving forward with testing of anti-GD2 + chemotherapy in the setting of relapsed/refractory disease as well as newly diagnosed high-risk neuroblastoma.

Efficacy and Perspectives of Anti-GD2 Therapy

Holger Lode will discuss ongoing clinical results using long-term-infusion of anti-GD2 mAb to avoid toxicity, associations of response with KIR and FcR genotype, development of vaccine approaches with an anti-idiotypic mAb (Ganglidiomab) and preclinical development with anti-GD2 mAb in combination with PD1 checkpoint blockade.

Identifying Predictive Immunological Biomarkers and Immuno-Oncology Combination to Improve Outcome of Anti-GD2 Therapy

Alice Yu will present recent correlative biology/immunology analyses for patients receiving the COG anti-GD2 + cytokine regimen, preclinical data pursuing other cytokine approaches, and potential applications for anti-GD2 treatment in other diseases.

Activation of Innate and Adaptive Immunity with Anti-GD2 and IL2

Paul Sondel will address KIR/KIR-ligand genotypes that are most associated with benefit from immunotherapy and preclinical ways anti-GD2 antibody plus cytokines and radiotherapy are allowing localized tumors to function as in situ vaccines.

Supported through a medical education grant by United Therapeutics

Neuroblastoma: Innovations on The Horizon

Saturday, May 12, 2018, 12:00-1:30 PM

Holger Lode MD, PhD (University Medicine Greifswald, Germany)

Ruth Ladenstein, MD (Children Cancer Research Institute, Vienna, Austria)
Rupert Handgretinger, MD (University of Tübingen, Germany)
Araz Marachelian, MD (University of California, Childrens Hospital Los Angeles, USA)
Juliet Gray, MD (University of Southampton, UK)

This workshop will explore the roles of altered mRNA translational regulation in cancer development, including how translation control influences adaptive responses to oncogenic stress, as well as pharmacological approaches to target the translation machinery in neuroblastoma.

Holger Lode will chair the symposium with four international pediatric hematologist oncologists and physician scientists to share their preclinical and clinical perspectives on novel combinations of anti-GD2 therapy.

Ruth Ladenstein will summarize recent data from SIOPEN studies that have combined novel delivery methods of anti-GD2 mAb with cytokine and present the SIOPEN approach for moving forward with testing of anti-GD2 and chemotherapy in newly diagnosed high-risk neuroblastoma.

Rupert Handgretinger will discuss rationale and ongoing clinical trials using anti-GD2 mAb in the context of haploidentical blood stem cell transplantation and share perspectives with novel anti-GD2 antibody constructs and combinations with IL-7 immunocytokines.

Araz Marachelian will present preclinical results and clinical developments to ehance efficacy of  anti-GD2 in combination with lenalidomide.

Juliet Gray will address the the scientific background of a clinical trail to combine PD1 immune checkpoint blockade and anti-GD2 antibody therapy in the context of mIBG therapy.

Supported through a medical education grant by EUSA Pharma

Want to Learn More About Registration?

Click here